Many clinicians lack familiarity with the diagnostic nuances and management strategies for interstitial lung disease (ILD), particularly in distinguishing subtypes (e.g., UIP vs. NSIP) and selecting appropriate treatment options, such as antifibrotics for fibrosing ILDs and avoiding immunosuppressants in idiopathic pulmonary fibrosis (IPF). Additionally, gaps exist in recognizing the role of multidisciplinary care and addressing social determinants of health to improve outcomes. This gap is compounded by evolving evidence, including findings from the INBUILD and PANTHER trials, which are often underutilized in clinical decision-making. Join the Core IM team as they discuss ILD and High-Risk Medication Prescribing: Gray Matters Segment.
- Provider:American College of Physicians
- Activity Link: https://www.acponline.org/
- Start Date: 2025-02-05 06:00:00
- End Date: 2025-02-05 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Internal Medicine
Subscribe
Login
0 Comments
Oldest